Physician profile
Gerald A Maguire
NPI 1144300302
$1,829,658.16
in general payments reported to CMS, 2019-2025
28 companies · $493K in 2025
The $493K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $217K · 2020: $72K · 2021: $21K · 2022: $145K · 2023: $390K · 2024: $492K · 2025: $493K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $956K · Consulting Fee: $230K · Travel and Lodging: $122K · Food and Beverage: $36K · Honoraria: $31K · Education: $60.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $955,758.25 |
| Consulting Fee | $229,781.00 |
| Travel and Lodging | $122,282.33 |
| Food and Beverage | $36,415.61 |
| Honoraria | $30,714.00 |
| Education | $60.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $336,324.82 | 2019-2025 | Ingrezza |
| Alkermes, INC. | $289,711.66 | 2021-2025 | Lybalvi, Aristada, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $261,005.64 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| E.R. Squibb & Sons, L.L.C. | $235,001.77 | 2024-2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $210,475.03 | 2020-2025 | Caplyta |
| Axsome Therapeutics, INC. | $173,622.60 | 2022-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $107,853.18 | 2024-2025 | Fanapt |
| Janssen Pharmaceuticals, INC | $98,289.17 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Sunovion Pharmaceuticals INC. | $66,001.79 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $21,029.65 | 2019-2025 | Uzedy |
| Acadia Pharmaceuticals INC | $9,811.36 | 2020 | |
| Eisai INC. | $8,385.00 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $6,067.64 | 2019-2022 | |
| Sage Therapeutics, LLC | $2,818.28 | 2021-2023 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $2,683.88 | 2019-2025 | Abilify Asimtufii, Rexulti, Rejoyn |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $287.27 | 2021-2024 | |
| Biogen, INC. | $102.20 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.59 | 2024 | |
| Indivior INC. | $41.87 | 2023 | Perseris |
| Novartis Pharmaceuticals Corporation | $36.25 | 2022 | |
| Allergan, INC. | $15.51 | 2019 |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Maguire listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.